Skip to main content
Evidence Snapshot

Glutamate carboxypeptidase 2

CHEMBL1892 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1892
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate carboxypeptidase 2 as ChEMBL target CHEMBL1892, mapped to UniProt Q04609. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate carboxypeptidase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1892
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q04609
Glutamate carboxypeptidase 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Glutamate carboxypeptidase 2 matters

As of 2026-09-13

Glutamate carboxypeptidase 2 is reviewed as Glutamate carboxypeptidase 2 (UniProt Q04609); Glutamate carboxypeptidase 2 shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 658 compounds, and 129 assays, with lead potency reaching pChEMBL 11.0.

Disease context
prostate cancer

Glutamate carboxypeptidase 2 shows approved-linked disease relevance led by prostate cancer. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include HUJ591 111IN, HUJ591 177LU, J591 177LU.

Start review with prostate cancer because it currently carries approved-linked support. Linked drugs include HUJ591 111IN, HUJ591 177LU, J591 177LU, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 5 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 658 compounds, and 129 assays for this target. The dominant activity type is IC50. CHEMBL6007312 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL6007312 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Glutamate carboxypeptidase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q04609, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why prostate cancer is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

658
Total Compounds
129
Total Assays
4
Approved Drugs
IC50: 366.0, KI: 326.0, EC50: 5.0, KD: 68.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL6007312
 11.0 Ki —
No preferred name
CHEMBL510924
 11.0 Ki —
No preferred name
CHEMBL5866602
 10.8 Ki —
No preferred name
CHEMBL3578202
 10.7 Ki Approved
No preferred name
CHEMBL5786057
 10.7 Ki —

Approved Drugs

Structure Compound First Approval
PIFLUFOLASTAT
CHEMBL4299851
 2021
GOZETOTIDE
CHEMBL3578202
 2020
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1892